Raymond James Initiates Coverage On Tvardi Therapeutics with Outperform Rating, Announces Price Target of $62
Benzinga Newsdesk 1 year ago
NewsPrice TargetInitiationAnalyst Ratings
Raymond James analyst Ryan Deschner initiates coverage on Tvardi Therapeutics (NASDAQ:TVRD) with a Outperform rating and announces Price Target of $62.
Raymond James analyst Ryan Deschner initiates coverage on Tvardi Therapeutics (NASDAQ:TVRD) with a Outperform rating and announces Price Target of $62.